GSK plc files 6-K

GSK plc announced positive Phase 3 data for bepirovirsen, an investigational treatment for chronic hepatitis B, showing unprecedented functional cure rates of 19% in the overall study population and 26% in a key subgroup, significantly outperforming the standard of care. Regulatory submissions are underway in multiple regions, with anticipated first decisions in Q3 2026.